| Old Articles: <Older 2381-2390 Newer> |
|---|
 |
The Motley Fool
September 27, 2005
Stephen D. Simpson |
Not Bracing for the Worst Price competition and tighter reimbursement? dj Orthopedics isn't worrying about them. Investors may not rush to sell, but they should perhaps start thinking about a protective stop-loss to lock on some easy profits.   |
The Motley Fool
September 27, 2005
Jack Uldrich |
A Ray of Hope for Flamel? New hepatitis C treatment offers a ray of hope to the ailing nanotech company. Unfortunately, this news does not guarantee sunnier days ahead. |
The Motley Fool
September 26, 2005
Stephen D. Simpson |
Boston Scientific: Finally Cheap Enough? Could shares of the medical device company now be attractive for long-term investors? |
Bio-IT World
September 2005
Kevin Davies |
Bringing Good Things to Informatics In interview with Nick Giannasi, Head of Informatics for GE Healthcare's Bio-Sciences division on how the company is shedding light on data integration in discovery and clinical trials. |
Bio-IT World
September 2005
Michael A. Greeley |
Harvesting Patient Data Longitudinal data tools will allow pharmaceuticals to optimize sales force deployments and distribution strategies based on medical impacts of their compounds across various population sets. |
Bio-IT World
September 2005
Alan Louie |
Molecular Imaging: Smarter and Better The expanding opportunity for molecular imaging (MI) technology to significantly improve drug development has not gone unobserved. Several drug development companies have added imaging capabilities to their arsenal of drug development tools. |
Bio-IT World
September 2005
John Russell |
BioSeek's MAP to Discovery Now, after roughly five years of platform development and building a database of assays, BioSeek seems poised for growth. |
Bio-IT World
September 2005
Mark D. Uehling |
Murky Diary Entries The FDA is planning to clarify the degree to which existing patient diary technologies are (or are not) encroaching on data-management duties formally assigned to clinical investigators. That guidance is in the works, with no known timetable. |
Bio-IT World
September 2005
John Russell |
Labor Pains and Gains Labor Day is the starting gun for the bio-science industry's race through the next year. Here are some up-and-coming items to watch: Transparency... Systems Biology... Crawford and McClellan... |
The Motley Fool
September 21, 2005
Stephen D. Simpson |
Can Biomet Stay Limber? Concerns about pricing have buffeted the orthopedic space and the No. 4 player in hips and knees. Whatever the case turns out to be, Biomet is probably a bit riskier than average. |
| <Older 2381-2390 Newer> Return to current articles. |
